Pharmacokinetic analysis of 6-O-[18F] FEE for PET imaging of EGFR mutation
D Shi, Y Dong, W Zhou, L Bai, J Huang, Y Han… - Bioorganic & Medicinal …, 2023 - Elsevier
O-[18 F] Fluoroethylerlotinib (6-O-[18 F] FEE), with a suitable half-life for commercial
distribution, may be a good replacement for [11 C] erlotinib to identify epidermal growth …
distribution, may be a good replacement for [11 C] erlotinib to identify epidermal growth …
In vivo PET Imaging of EGFR Expression: An Overview of Radiolabeled EGFR TKIs
J Zhu, Y Li, X Wu, Y Li, L Wang… - Current Topics in …, 2022 - ingentaconnect.com
With the development of epidermal growth factor receptor (EGFR)-based tyrosine kinase
inhibitors (TKIs) and their applications in the clinic, non-small-cell lung cancer (NSCLC) …
inhibitors (TKIs) and their applications in the clinic, non-small-cell lung cancer (NSCLC) …
[11C] Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
A Traxl, T Beikbaghban, T Wanek, K Kryeziu… - Nuclear Medicine and …, 2017 - Elsevier
Abstract Introduction [11 C] Erlotinib PET has shown promise to distinguish non-small cell
lung cancer (NSCLC) tumors harboring the activating epidermal growth factor receptor …
lung cancer (NSCLC) tumors harboring the activating epidermal growth factor receptor …
18F⁃脱氧葡萄糖正电子发射计算机断层扫描显像在预测肺鳞癌表皮生长因子受体突变中的价值.
赵承勇， 邓小毅， 王洪松， 曹国平… - Chinese Journal of …, 2021 - search.ebscohost.com
目的探讨18F⁃ 脱氧葡萄糖(18F⁃ FDG) 正电子发射计算机断层扫描(PET⁃ CT)
显像在预测肺鳞癌表皮生长因子受体(EGFR) 突变中的价值. 方法回顾性分析2013 年6 …
显像在预测肺鳞癌表皮生长因子受体(EGFR) 突变中的价值. 方法回顾性分析2013 年6 …
Radiosynthesis and preclinical evaluation of [18F] FEM as a potential novel PET probe for tumor imaging
Y Jiang, W Zhou, K Hu, Y Han, P Sun, Q Wang… - Bioorganic & Medicinal …, 2020 - Elsevier
In the 21st century, the incidence and mortality of cancer, one of the most challenging
diseases in the world, have rapidly increased. The purpose of this study was to develop 2-(2 …
diseases in the world, have rapidly increased. The purpose of this study was to develop 2-(2 …
PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?
VH Gerbaudo, CK Kim - Nuclear medicine and molecular imaging, 2017 - Springer
The increased understanding of the molecular pathology of different malignancies,
especially lung cancer, has directed investigational efforts to center on the identification of …
especially lung cancer, has directed investigational efforts to center on the identification of …
Identifying nonsmall‐cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging
JL Goggi, A Haslop, B Ramasamy… - Journal of Labelled …, 2019 - Wiley Online Library
Specific mutations significantly affect response to epidermal growth factor tyrosine kinase
inhibitor (EGFR‐TKI) treatment in lung cancer patients. Identifying patients with these …
inhibitor (EGFR‐TKI) treatment in lung cancer patients. Identifying patients with these …
[HTML][HTML] 非小细胞肺癌分子靶向EGFR-TKI 治疗敏感性与治疗耐受性预测筛选的分子显像研究现状及进展
戴东， 徐文贵， 王琦， 李小凤， 朱研佳 - Chinese Journal of Lung …, 2017 - ncbi.nlm.nih.gov
肺癌80% 以上为非小细胞肺癌（ non-small cell lung cancer, NSCLC）， 表皮生长因子受体（
epidermal growth factor receptor, EGFR） 介导的信号通路与NSCLC 发生发展密切相关 …
epidermal growth factor receptor, EGFR） 介导的信号通路与NSCLC 发生发展密切相关 …
[HTML][HTML] 非小细胞肺癌EGFR 突变的分子影像学在体检测
罗丹静， 马进安， 张锦明， 赵颜忠 - Chinese Journal of Lung …, 2017 - ncbi.nlm.nih.gov
靶向药物表皮生长因子受体酪氨酸激酶抑制剂（ epidermal growth factor receptor tyrosine
kinase inhibitor, EGFR-TKI） 改变了非小细胞肺癌的治疗格局， 研究表明只有EGFR …
kinase inhibitor, EGFR-TKI） 改变了非小细胞肺癌的治疗格局， 研究表明只有EGFR …
Current Status and Progress in Molecular Imaging of Non-small Cell Lung Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and Treatment Tolerance …
DAI Dong, XU Wengui, W Qi, LI Xiaofeng… - Zhongguo Fei Ai …, 2017 - search.proquest.com
肺癌 80% 以上为非小细胞肺癌 (non-small cell lung cancer, NSCLC), 表皮生长因子受体
(epidermal growth factor receptor, EGFR) 介导的信号通路与 NSCLC 发生发展密切相关. 针对 …
(epidermal growth factor receptor, EGFR) 介导的信号通路与 NSCLC 发生发展密切相关. 针对 …